PLx Pharma (NASDAQ:PLXP) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 7.5 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $6.60 million which beat the analyst consensus estimate of $4.10 million by 60.98 percent.
PLx Pharma Q3 Adj. EPS $(0.37) Beats $(0.46) Estimate, Sales $6.60M Beat $4.10M Estimate
PLx Pharma (NASDAQ:PLXP) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 7.5 percent increase over losses of $(0.40) per share from the same
